DDInter1381 DDInter1676
Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749]
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Paliperidone {u} (Compound) resembles {v} (Compound) Risperidone
Paliperidone {u} (Compound) binds {v} (Gene) DRD2
Paliperidone {u} (Compound) palliates {v} (Disease) schizophrenia
Paliperidone {u} (Compound) causes {v} (Side Effect) Skin discolouration
Paliperidone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Paliperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eribulin
Paliperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Paliperidone {u} may lead to a major life threatening interaction when taken with {v} Metoclopramide
Paliperidone {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Paliperidone (Compound) resembles Risperidone (Compound)
Paliperidone (Compound) binds DRD2 (Gene)
Paliperidone (Compound) palliates schizophrenia (Disease)
Paliperidone (Compound) causes Skin discolouration (Side Effect)
Paliperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Paliperidone may lead to a major life threatening interaction when taken with Metoclopramide
Paliperidone may lead to a major life threatening interaction when taken with Vemurafenib